drugset
drugset / Trial / NCT07105319

Ropeginterferon for Treatment Free Remission

NCT07105319 ↗

Phase 4 Completed 65 enrolled Dong-Wook Kim
Non-randomizedSingle-groupOpen-labelOther

Summary

Ropeginterferon is a long-acting next-generation mono-pegylated interferon alfa-2b consisting of one isoform produced by PharmaEssentia Co. and the pegylated (PEG) formulations that require less frequent administration and have improved efficacy and tolerability. In this study, patients in the investigational arm will receive Ropeginterferon subcutaneously with 250 μg at week 0, 350 μg at week 2, 500 μg at week 4, and thereafter 500 μg bi-weekly until week 24.

Timeline

Start
2021-11-30
Primary completion
2025-07-30
Completion
2025-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ropeginterferon Protein / enzyme biologic 500 ug Subcutaneous

Indications

chronic myeloid leukemia